HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

Affiliations

¹ Department of Surgery and Cancer, Gynecologic Oncology, Hammersmith Hospital Imperial College London, London, UK; Department of Gynecology, Charité Medical University of Berlin, Berlin; North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group, Taufkirchen, Germany; Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany. Electronic address: c.fotopoulou@imperial.ac.uk.
² Department of Gynecology, Charité Medical University of Berlin, Berlin; North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group, Taufkirchen, Germany; Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany.
³ Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany; Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, München, Germany.
⁴ Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany; Department of Gynecology, Kliniken Essen Mitte, Essen, Germany.
⁵ University Hospitals Leuven, Leuven, Belgium; BGOG, Leuven, Belgium.
⁶ Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; GEICO Study Group, Madrid, Spain.
⁷ GEICO Study Group, Madrid, Spain; Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, Madrid, Spain.

Free article

Editorial

C Fotopoulou et al. Ann Oncol. 2018.

Free article

. 2018 Aug 1;29(8):1610-1613.

doi: 10.1093/annonc/mdy198.

¹ Department of Surgery and Cancer, Gynecologic Oncology, Hammersmith Hospital Imperial College London, London, UK; Department of Gynecology, Charité Medical University of Berlin, Berlin; North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group, Taufkirchen, Germany; Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany. Electronic address: c.fotopoulou@imperial.ac.uk.
² Department of Gynecology, Charité Medical University of Berlin, Berlin; North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group, Taufkirchen, Germany; Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany.
³ Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany; Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, München, Germany.
⁴ Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Taufkirchen, Germany; Department of Gynecology, Kliniken Essen Mitte, Essen, Germany.
⁵ University Hospitals Leuven, Leuven, Belgium; BGOG, Leuven, Belgium.
⁶ Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain; GEICO Study Group, Madrid, Spain.
⁷ GEICO Study Group, Madrid, Spain; Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, Madrid, Spain.

No abstract available

Comment on

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. van Driel WJ, et al. N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618. N Engl J Med. 2018. PMID: 29342393 Clinical Trial.